Cargando…

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies

Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two major clinical forms. The global incidence and prevalence of IBD have increased over the last...

Descripción completa

Detalles Bibliográficos
Autores principales: Bretto, Elisabetta, Ribaldone, Davide Giuseppe, Caviglia, Gian Paolo, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Frara, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452708/
https://www.ncbi.nlm.nih.gov/pubmed/37626745
http://dx.doi.org/10.3390/biomedicines11082249
_version_ 1785095738789724160
author Bretto, Elisabetta
Ribaldone, Davide Giuseppe
Caviglia, Gian Paolo
Saracco, Giorgio Maria
Bugianesi, Elisabetta
Frara, Simone
author_facet Bretto, Elisabetta
Ribaldone, Davide Giuseppe
Caviglia, Gian Paolo
Saracco, Giorgio Maria
Bugianesi, Elisabetta
Frara, Simone
author_sort Bretto, Elisabetta
collection PubMed
description Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two major clinical forms. The global incidence and prevalence of IBD have increased over the last 2–4 decades. Despite the specific etiopathogenesis of IBD still being unknown, it is widely recognized that immunological, genetic, and environmental factors are implicated. A greater understanding of the multiple signaling pathways involved has led to the development of biologic therapies in the last two decades. Although these treatments have dramatically transformed the course of IBD, there is not a definitive cure and available therapies may cause adverse events (AEs), limiting their use, or have an inadequate effect in some patients. In this context, emerging therapies addressing new specific pathogenetic mechanisms have shown promising efficacy and safety data in early clinical trials. The purpose of this review is to highlight the available clinical trial data for these new drugs, such as more preferential JAK inhibitors, anti-IL-23 antibodies, sphingosine-1-phosphate receptor modulators, anti-integrin therapies, and other small molecules that are currently under research. We will emphasize the potential significance of these agents in shaping future treatment options.
format Online
Article
Text
id pubmed-10452708
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104527082023-08-26 Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies Bretto, Elisabetta Ribaldone, Davide Giuseppe Caviglia, Gian Paolo Saracco, Giorgio Maria Bugianesi, Elisabetta Frara, Simone Biomedicines Review Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two major clinical forms. The global incidence and prevalence of IBD have increased over the last 2–4 decades. Despite the specific etiopathogenesis of IBD still being unknown, it is widely recognized that immunological, genetic, and environmental factors are implicated. A greater understanding of the multiple signaling pathways involved has led to the development of biologic therapies in the last two decades. Although these treatments have dramatically transformed the course of IBD, there is not a definitive cure and available therapies may cause adverse events (AEs), limiting their use, or have an inadequate effect in some patients. In this context, emerging therapies addressing new specific pathogenetic mechanisms have shown promising efficacy and safety data in early clinical trials. The purpose of this review is to highlight the available clinical trial data for these new drugs, such as more preferential JAK inhibitors, anti-IL-23 antibodies, sphingosine-1-phosphate receptor modulators, anti-integrin therapies, and other small molecules that are currently under research. We will emphasize the potential significance of these agents in shaping future treatment options. MDPI 2023-08-11 /pmc/articles/PMC10452708/ /pubmed/37626745 http://dx.doi.org/10.3390/biomedicines11082249 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bretto, Elisabetta
Ribaldone, Davide Giuseppe
Caviglia, Gian Paolo
Saracco, Giorgio Maria
Bugianesi, Elisabetta
Frara, Simone
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title_full Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title_fullStr Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title_full_unstemmed Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title_short Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
title_sort inflammatory bowel disease: emerging therapies and future treatment strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452708/
https://www.ncbi.nlm.nih.gov/pubmed/37626745
http://dx.doi.org/10.3390/biomedicines11082249
work_keys_str_mv AT brettoelisabetta inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies
AT ribaldonedavidegiuseppe inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies
AT cavigliagianpaolo inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies
AT saraccogiorgiomaria inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies
AT bugianesielisabetta inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies
AT frarasimone inflammatoryboweldiseaseemergingtherapiesandfuturetreatmentstrategies